Advance the use and funding of FDA-approved medicines to treat serious mental illness; protecting patient access to mental health medications in public programs
2026 · 3rd Quarter (July 1 - Sep 30)
ALKERMES, INC.
Filed by SPLITOAK STRATEGIES LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 19, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- SPLITOAK STRATEGIES LLC
- Client
- ALKERMES, INC.
- Filing UUID
- 96f853b7-7c33-459d-ba4a-534ca3289c8f
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.